World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
39936
World Ranking
13885
National Ranking
448

Valérie Boige publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Valérie Boige sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 399 publications — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Valérie Boige D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Valérie Boige sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Valérie Boige is affiliated with the Institut Gustave Roussy in France and has an extensive research portfolio primarily in the field of Medicine, with a focus on Oncology. Their scholarly output includes significant contributions to the study of cancer treatments, particularly colorectal cancer, hepatocellular carcinoma, pancreatic and hepatic oncology, as well as gastric cancer management.

Their work covers various subfields such as oncology, surgery, pulmonary and respiratory medicine, hepatology, and cancer research. Boige's research topics emphasize colorectal cancer treatments and studies, hepatocellular carcinoma treatment and prognosis, pancreatic and hepatic oncology research, cancer genomics and diagnostics, colorectal and anal carcinomas, gastric cancer management and outcomes, and cancer treatment and pharmacology.

Boige has published notable papers including:

  • Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial, 2021, The Lancet Oncology
  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial, 2023, The Lancet Oncology
  • Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma, 2024, Annals of Oncology
  • Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study, 2020, The Lancet Oncology
  • Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial, 2020, Journal of Clinical Oncology

Frequent collaborators in Boige's research include:

  • Antoine Hollebecque
  • Michel Ducreux
  • Cristina Smolenschi
  • Alice Boilève
  • David Malka

The venues where Boige's research is regularly published demonstrate a pattern of engagement with well-established oncology and cancer research journals. Key publication venues include:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • European Journal of Cancer
  • Cancers
  • Annals of Surgical Oncology

Boige's research contributions integrate clinical trials, chemotherapy protocols, immunotherapy, surgical oncology, and diagnostic advances. This body of work addresses therapeutic strategies for several gastrointestinal cancers, underpinning treatment advances in locally advanced rectal cancer, advanced gastric cancer, hepatocellular carcinoma, and colorectal peritoneal metastases.

Best Publications

  • The consensus molecular subtypes of colorectal cancer

    Justin Guinney;Rodrigo Dienstmann;Rodrigo Dienstmann;Xingwu Wang;Xingwu Wang;Aurélien De Reyniès

  • KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

    Astrid Lièvre;Jean-Baptiste Bachet;Delphine Le Corre;Valérie Boige

  • Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial

    Marc Ychou;Valérie Boige;Jean-Pierre Pignon;Thierry Conroy

  • KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

    Astrid Lièvre;Jean-Baptiste Bachet;Valérie Boige;Anne Cayre

  • Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value

    Laetitia Marisa;Aurélien de Reyniès;Alex Duval;Alex Duval;Janick Selves

  • Immunogenic death of colon cancer cells treated with oxaliplatin.

    A. Tesniere;F. Schlemmer;F. Schlemmer;F. Schlemmer;V. Boige;O. Kepp;O. Kepp;O. Kepp

  • Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

    Pierre Laurent-Puig;Anne Cayre;Gilles Manceau;Emmanuel Buc

  • Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

    Thierry Conroy;Jean-François Bosset;Pierre-Luc Etienne;Emmanuel Rio

  • Cutaneous side-effects of kinase inhibitors and blocking antibodies

    Caroline Robert;Jean-Charles Soria;Alain Spatz;Axel Le Cesne

  • Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

    Josep M. Llovet;Thomas Decaens;Jean-Luc Raoul;Eveline Boucher

  • Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901

    Christophe Mariette;Laetitia Dahan;Françoise Mornex;Emilie Maillard

  • Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.

    D. Elias;F. Blot;A. El Otmany;S. Antoun

  • Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year.

    Thierry de Baere;Dominique Elias;Clarisse Dromain;Mostafa Gamal El Din

  • Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

    Sophie Gourgou-Bourgade;Caroline Bascoul-Mollevi;Françoise Desseigne;Marc Ychou

  • Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.

    Clarisse Dromain;Thierry de Baere;Jean Lumbroso;Hubert Caillet

  • Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

    Erika Vacchelli;Yuting Ma;Elisa E. Baracco;Antonella Sistigu

  • Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

    Thierry Conroy;Marie-Pierre Galais;Jean-Luc Raoul;Olivier Bouché

  • Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation.

    Thierry de Baère;Jean Palussière;Anne Aupérin;Antoine Hakime

  • Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up.

    Clarisse Dromain;Thierry de Baere;Dominique Elias;Viseth Kuoch

  • Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases

    T. de Baère;A. Aupérin;F. Deschamps;P. Chevallier

Frequent Co-Authors

Michel Ducreux
Michel Ducreux Institut Gustave Roussy
David Malka
David Malka Institut Mutualiste Montsouris
Dominique Elias
Dominique Elias Institut Gustave Roussy
Pierre Laurent-Puig
Pierre Laurent-Puig Université Paris Cité
Olivier Bouché
Olivier Bouché CHU de Reims
Julien Taieb
Julien Taieb Université Paris Cité
Thierry de Baere
Thierry de Baere Institut Gustave Roussy
François Ghiringhelli
François Ghiringhelli Centre Georges François Leclerc
Philippe Rougier
Philippe Rougier University of Nantes
Jean-Luc Raoul
Jean-Luc Raoul Institut de Cancérologie de l'Ouest (ICO)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in Medicine doesn't always mean attending traditional medical school. There are many flexible, online programs that align well with a variety of healthcare goals.

For those pursuing advanced nursing roles, asn to fnp programs allow registered nurses to bridge to a family nurse practitioner specialty. If your interests are more focused on nutrition and wellness, earning an online degree in nutrition can open opportunities in clinical, community, or corporate settings.

For aspiring healthcare leaders, the best mha programs offer online pathways to earn a Master of Health Administration, preparing you for management in hospitals and healthcare organizations. Meanwhile, practicing RNs with limited time for on-site requirements can complete their BSN via rn to bsn programs without clinicals.

Each of these online degrees expands your healthcare career options and provides flexibility to balance work, study, and personal responsibilities.

Best Scientists Citing Valérie Boige

Trending Scientists

Recently Published Articles